Palme Carsten E, Waseem Zeeshan, Raza S Naweed, Eski Spiro, Walfish Paul, Freeman Jeremy L
Department of Otolaryngology-Head and Neck Surgery, Mount Sinai Hospital, Toronto, Ontario, Canada.
Arch Otolaryngol Head Neck Surg. 2004 Jul;130(7):819-24. doi: 10.1001/archotol.130.7.819.
The AMES (age, distant metastasis, tumor extent, and size), AGES (age, tumor size, histologic grade, tumor extent, distant metastasis), and MACIS (distant metastasis, age, completeness of primary tumor resection, local invasion, and tumor size) prognostic systems for well-differentiated thyroid carcinoma (WDTC) are well known. The development of disease recurrence is associated with a poor outcome; however, the prognostic importance of multiple treatment failures has not been clearly reported.
To identify patient, tumor, and treatment factors that may be associated with the development of multiple recurrences in WDTC.
All patients treated for residual or recurrent WDTC were retrospectively identified from the thyroid cancer database at the Department of Otolaryngology-Head and Neck Surgery, Mount Sinai Hospital, Toronto, Ontario (1963-2000). Data on relevant patient, tumor, and treatment factors were collected.
Patient, tumor, and treatment factors predicting the development of multiple treatment failures, disease-specific survival, and overall survival.
A total of 574 patients (115 male, 459 female; median age, 42 years [range, 9-92 years]) were identified, whose final histopathologic diagnosis was papillary carcinoma in 468, follicular carcinoma in 76, and mixed in 30 cases. TNM staging was as follows: 409 (71%) stage I, 66 (12%) stage II, 68 (12%) stage III, and 31 (5%) stage IV. Initial management included total thyroidectomy for 217 patients (38%), subtotal thyroidectomy for 357 (62%), and adjuvant iodine 131 therapy for 492 (86%). Seventy-three patients (13%) developed recurrent WDTC (21 male, 52 female; median age, 44 years [range, 18-84 years]). Patients were divided into 3 groups: group 1 (no recurrence, n = 501), group 2 (1 recurrence only, n = 42), and group 3 (multiple recurrences, n = 31). Group 2 data were as follows: site of recurrence (locoregional, 25; distant, 7; unspecified, 10) and treatment (surgery, 12; iodine 131, 42) and for group 3: site of first recurrence (locoregional, 16; distant, 11; unspecified, 4) and treatment (surgery, 14, iodine 131, 22; palliation, 1). Actuarial disease-specific survival at 20 years was 100%, 94%, and 60%, respectively, for the 3 groups (median follow-up, 7 years; range, 1-34 years). Male sex, advanced stage, extrathyroidal spread, and primary treatment with total thyroidectomy were predictive factors for multiple recurrences on multivariate regression (all P<.05).
Male sex, advanced initial stage, and presence of extrathyroidal spread within the primary tumor are the most significant independent predictors of developing multiple recurrences in patients with WDTC. These patients have a poor prognosis with a significant reduction in tumor-free survival.
分化型甲状腺癌(WDTC)的AMES(年龄、远处转移、肿瘤范围和大小)、AGES(年龄、肿瘤大小、组织学分级、肿瘤范围、远处转移)和MACIS(远处转移、年龄、原发肿瘤切除完整性、局部侵犯和肿瘤大小)预后系统广为人知。疾病复发的发生与不良预后相关;然而,多次治疗失败的预后重要性尚未有明确报道。
确定可能与WDTC多次复发发生相关的患者、肿瘤和治疗因素。
从安大略省多伦多市西奈山医院耳鼻咽喉头颈外科的甲状腺癌数据库中,回顾性确定所有接受残余或复发性WDTC治疗的患者(1963 - 2000年)。收集有关患者、肿瘤和治疗因素的数据。
预测多次治疗失败发生、疾病特异性生存和总生存的患者、肿瘤和治疗因素。
共确定574例患者(男115例,女459例;中位年龄42岁[范围9 - 92岁]),其最终组织病理学诊断为乳头状癌468例,滤泡状癌76例,混合性30例。TNM分期如下:I期409例(71%),II期66例(12%),III期68例(12%),IV期31例(5%)。初始治疗包括217例患者(38%)行全甲状腺切除术,357例(62%)行次全甲状腺切除术,492例(86%)接受辅助碘131治疗。73例患者(13%)发生复发性WDTC(男21例,女52例;中位年龄44岁[范围18 - 84岁])。患者分为3组:第1组(无复发,n = 501),第2组(仅1次复发,n = 42),第3组(多次复发,n = 31)。第2组数据如下:复发部位(局部区域,25例;远处,7例;未明确,10例)和治疗(手术,12例;碘131,42例),第3组:首次复发部位(局部区域,16例;远处,11例;未明确,4例)和治疗(手术,14例,碘131,22例;姑息治疗,1例)。3组患者20年精算疾病特异性生存率分别为100%、94%和60%(中位随访7年;范围1 - 34年)。多因素回归分析显示,男性、晚期、甲状腺外侵犯以及初次治疗行全甲状腺切除术是多次复发的预测因素(均P <.05)。
男性、初始晚期以及原发肿瘤存在甲状腺外侵犯是WDTC患者发生多次复发的最显著独立预测因素。这些患者预后较差,无瘤生存期显著缩短。